Endovascular Therapy for Post-Thrombotic Syndrome - A Randomized Trial.
Summary
Online ahead of print. Original Article Abstract Background Post-thrombotic syndrome is common after deep-vein thrombosis and can cause severe symptoms involving the limbs that impair patients' activity and quality of life. Endovascular therapy can eliminate chronic venous obstruction and is hypothesized to reduce the severity of post-thrombotic syndrome. Methods We randomly assigned 225 patients with moderate or severe post-thrombotic syndrome and imaging-confirmed iliac-vein obstructi
Content
# Online ahead of print.
*Original Article*
# Abstract
## Background
Post-thrombotic syndrome is common after deep-vein thrombosis and
can cause severe symptoms involving the limbs that impair patients' activity and
quality of life. Endovascular therapy can eliminate chronic venous obstruction
and is hypothesized to reduce the severity of post-thrombotic syndrome.
## Methods
We randomly assigned 225 patients with moderate or severe
post-thrombotic syndrome and imaging-confirmed iliac-vein obstruction to receive
endovascular therapy (iliac-vein stent placement and enhanced antithrombotic
therapy) plus standard post-thrombotic syndrome care or standard post-thrombotic
syndrome care alone. The severity of post-thrombotic syndrome at 6 months (the
primary outcome) was assessed with the validated Venous Clinical Severity Score
(VCSS) tool (scores range from 0 to 30, with higher scores indicating more
severe post-thrombotic syndrome) by evaluators who were unaware of the group
assignments. Key secondary outcomes included venous disease-specific and overall
quality of life.
## Results
At 6 months, the severity of post-thrombotic syndrome was lower in the
endovascular-therapy group than in the no-endovascular-therapy group (mean [±SD]
VCSS, 8.1±5.1 vs. 10.0±4.9; adjusted difference, -2.0; P = 0.001). Venous
disease-specific quality of life as assessed with the Venous Insufficiency
Epidemiological and Economic Study Quality of Life questionnaire was better in
the endovascular-therapy group than in the no-endovascular-therapy group at 6
months (adjusted difference, 14.5 points; P<0.001), as was overall quality of
life as assessed with the Medical Outcomes Study 36-Item Short-Form Health
Status Survey physical component summary score (adjusted difference, 6.1 points;
P<0.001); scores on both tools range from 0 to 100. Through 6 months, bleeding
was more common in the endovascular-therapy group than in the
no-endovascular-therapy group (in 11.6% vs. 3.6% of the patients; P = 0.03).
## Conclusions
Among patients with moderate or severe post-thrombotic syndrome and
iliac-vein obstruction, endovascular therapy led to less severe post-thrombotic
syndrome and better health-related quality of life than standard care over a
6-month period but with a higher risk of bleeding. (Funded by the National
Heart, Lung, and Blood Institute and others; C-TRACT ClinicalTrials.gov number,
NCT03250247.).
---
DOI: 10.1056/NEJMoa2519001